Modeling Preventative Strategies against Human Papillomavirus-Related Disease in Developed Countries

Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States

2011 • 3,261 citations

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

2010 • 2,440 citations

Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement

2012 • 2,379 citations

Global burden of cancers attributable to infections in 2008: a review and synthetic analysis

2012 • 2,351 citations

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

2009 • 1,580 citations

Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males

2011 • 1,043 citations

Screening for Cervical Cancer: U.S. Preventive Services Task Force Recommendation Statement

2012 • 962 citations

HPV Vaccine against Anal HPV Infection and Anal Intraepithelial Neoplasia

2011 • 877 citations

Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study

2011 • 822 citations

Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer

2004 • 772 citations

The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV‐Naive Women Aged 16–26 Years

2009 • 626 citations

Cost-Effectiveness of Cervical Cancer Screening With Human Papillomavirus DNA Testing and HPV-16,18 Vaccination

2008 • 445 citations

Recommendations on the use of quadrivalent human papillomavirus vaccine in males--Advisory Committee on Immunization Practices (ACIP), 2011.

2011 • 389 citations

Evaluating Human Papillomavirus Vaccination Programs

2004 • 388 citations

Comparison of the immunogenicity and safety ofCervarix™ andGardasil^®human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years

2009 • 386 citations

Health and Economic Implications of HPV Vaccination in the United States

2008 • 362 citations

An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results

2008 • 334 citations

Incidence and Epidemiology of Anal Cancer in the Multicenter AIDS Cohort Study

2008 • 332 citations

Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine

2011 • 314 citations

Epidemiology of HPV 16 and Cervical Cancer in Finland and the Potential Impact of Vaccination: Mathematical Modelling Analyses

2006 • 286 citations

Economic evaluation of human papillomavirus vaccination in the United Kingdom

2008 • 279 citations

Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States

2009 • 229 citations

Impact of vaccinating boys and men against HPV in the United States

2010 • 218 citations

The cost-effectiveness of male HPV vaccination in the United States

2011 • 199 citations

Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis

2010 • 186 citations

The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada

2007 • 181 citations

Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes

2006 • 163 citations

Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing

2007 • 144 citations

National and state vaccination coverage among adolescents aged 13 through 17 years--United States, 2010.

2011 • 141 citations

Cost-effectiveness of Human Papillomavirus Vaccination in the United States

2008 • 134 citations

Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model

2011 • 118 citations

Modeling Cervical Cancer Prevention in Developed Countries

2008 • 117 citations

Incremental Impact of Adding Boys to Current Human Papillomavirus Vaccination Programs: Role of Herd Immunity

2011 • 115 citations

Modeling Human Papillomavirus Vaccine Effectiveness: Quantifying the Impact of Parameter Uncertainty

2007 • 113 citations

Economic Evaluation of Human Papillomavirus Vaccination in Developed Countries

2009 • 104 citations

Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia

2011 • 102 citations

Cost-Effectiveness of Human Papillomavirus Vaccination and Cervical Cancer Screening in Women Older Than 30 Years in the United States

2009 • 97 citations

Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: a cost-effectiveness analysis

2008 • 87 citations

Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland

2007 • 86 citations

The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK

2008 • 86 citations

Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France

2008 • 85 citations

Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20–29 in the UK

2010 • 84 citations

Efficacy, duration of immunity and cross protection after HPV vaccination: A review of the evidence

2009 • 80 citations

Cost-Effectiveness Analysis of Human Papillomavirus Vaccination in the Netherlands

2009 • 74 citations

Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark

2010 • 71 citations

The health and economic effects of HPV DNA screening in The Netherlands

2010 • 66 citations

Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: A multi-regional health economic analysis

2008 • 64 citations

Sex-Specific Immunization for Sexually Transmitted Infections Such as Human Papillomavirus: Insights from Mathematical Models

2011 • 63 citations

The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia

2011 • 63 citations

Until Which Age Should Women Be Vaccinated Against HPV Infection? Recommendation Based on Cost-effectiveness Analyses

2011 • 55 citations

Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria

2009 • 54 citations

Health and economic impact associated with a quadrivalent HPV vaccine in Italy

2008 • 52 citations

Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands

2007 • 49 citations

Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland

2008 • 47 citations

Cervical cancer screening in Australia: modelled evaluation of the impact of changing the recommended interval from two to three years

2010 • 45 citations

A cost–utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme

2009 • 44 citations

Cost-effectiveness of human papillomavirus vaccination and screening in Spain

2010 • 41 citations

Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination

2008 • 41 citations

Cost-effectiveness of different human papillomavirus vaccines in Singapore

2011 • 41 citations

HPV16/18 vaccination to prevent cervical cancer in The Netherlands: Model‐based cost‐effectiveness

2008 • 39 citations

Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model

2008 • 37 citations

Potential effects of decreased cervical cancer screening participation after HPV vaccination: An example from the U.S.

2007 • 37 citations

The 19th International Papillomavirus Conference

2002 • 36 citations

Cost-effectiveness of human papillomavirus vaccination in Belgium: Do not forget about cervical cancer screening

2009 • 32 citations

Impact of vaccine protection against multiple HPV types on the cost-effectiveness of cervical screening

2012 • 31 citations

Age-Based Programs for Vaccination against HPV

2009 • 31 citations

For Cancers Caused by HPV, Two Vaccines Were Just the Beginning

2011 • 30 citations

A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer

2010 • 30 citations

Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: Adaptation of an existing cohort model to the situation in the Netherlands

2009 • 29 citations

The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands

2011 • 28 citations

Assessment of the cost–effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model

2008 • 28 citations

Cost–consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: The potential impact of different cross-protection profiles

2011 • 27 citations

Modelling patterns of clearance of HPV-16 infection and vaccination efficacy

2010 • 26 citations

Would the effect of HPV vaccination on non-cervical HPV-positive cancers make the difference for its cost-effectiveness?

2010 • 25 citations

The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary

2010 • 25 citations

The Health Technology Assessment of bivalent HPV vaccine Cervarix® in Italy

2010 • 25 citations

Cost-Effectiveness of Cervical Cancer Prevention in Central and Eastern Europe and Central Asia

2013 • 22 citations

Cost-effectiveness of a tetravalent human papillomavirus vaccine in Germany

2008 • 20 citations

Modelling the economic value of cross- and sustained-protection in vaccines against cervical cancer

2010 • 16 citations

UK will use Gardasil in its HPV vaccination programme from next September

2011 • 4 citations

Response Re: Cost-Effectiveness Analysis of Human Papillomavirus Vaccination in the Netherlands

2010 • 1 citations

Response: Re: Cost-Effectiveness Analysis of Human Papillomavirus Vaccination in the Netherlands

2009 • 1 citations